Table 5. .
Expression of Total RPS24 mRNA Related to GAPDH in Lymphoblastoid Cell Lines in Diseased and Control Samples[Note]
| Sample Group and Sample ID(s) |
RPS24 Average CT | GAPDH Average CT | ΔCT RPS24 − GAPDH | ΔΔCT (ΔCT−ΔCT,C) | RPS24 Normalized to GAPDH (2-ΔΔCT) |
| Controls: | |||||
| C1–C4 | 20.13 ± .66 | 16.38 ± .36 | 3.94 ± .76 | .00 ± 1.07 | 1.0 (.48–2.10) |
| RPS24-mutated samples: | |||||
| D1 | 22.39 ± .28 | 17.56 ± .22 | 4.84 ± .36 | .90 ± .84 | .54 (.30–.96) |
| D2 | 20.83 ± .31 | 17.44 ± .17 | 3.39 ± .35 | −.55 ± .83 | 1.47 (.82–2.61) |
| D3 | 20.82 ± .33 | 16.25 ± .31 | 4.67 ± .45 | .73 ± .88 | .60 (.33–1.11) |
| RPS19-mutated samples: | |||||
| D4 | 19.68 ± .35 | 16.38 ± .24 | 3.30 ± .42 | −.64 ± .87 | 1.56 (.86–2.84) |
| D5 | 20.54 ± .38 | 18.21 ± .14 | 2.34 ± .41 | −1.60 ± .86 | 3.04 (1.67–5.51) |
| D6 | 20.50 ± .69 | 16.35 ± .27 | 4.14 ± .74 | .20 ± 1.06 | .87 (.42–1.81) |
| Non–RPS19/RPS24-mutated samples: | |||||
| D7 | 20.80 ± .82 | 17.20 ± .40 | 3.60 ± .91 | −.34 ± 1.18 | 1.27 (.56–2.87) |
| D8 | 20.80 ± .71 | 18.69 ± .36 | 2.11 ± .80 | −1.83 ± 1.10 | 3.56 (1.66–7.61) |
| D9 | 19.86 ± .33 | 16.49 ± .23 | 3.37 ± .40 | −.57 ± .85 | 1.49 (.82–2.69) |
| D10 | 19.45 ± .46 | 17.16 ± .35 | 2.29 ± .57 | −1.65 ± .95 | 3.15 (1.63–6.08) |
Note.— C1–C4 are control samples, and D1–D10 are diseased samples. CT = number of cycles; CT,C = number of control cycles.